Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Celularity IncCELU · Entity 7145 | Director | January 12, 2026 | January 15, 2026 |
| GYRE THERAPEUTICS, INC.CBIO · Entity 5247 | Director | January 07, 2022 | January 07, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Celularity Inc
Report date January 12, 2026 · Filed January 15, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 256,026 |
Reported balance
After 2026-01-12 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-01-12 · Grant · Acquired 19,231 · Balance 256,026 F1: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest immediately upon grant. F2: Includes 19,231 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest immediately upon grant. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest immediately upon grant.
F2: Includes 19,231 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest immediately upon grant.
GYRE THERAPEUTICS, INC.
Report date January 07, 2022 · Filed January 07, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,790 |
Reported balance
After 2022-01-07 transaction · row 1
1 source rowRow 1 · 2022-01-07 · Grant · Acquired 12,855 · Balance 31,790 F1: Represents shares of common stock received in lieu of fees. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock received in lieu of fees.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 12, 2026 Filed Jan 15, 2026 01:55 UTC | Celularity Inc CELU · Entity 7145 | GrantClass A Common Stock | 19,231 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-002303 · ownership.xml · nonDerivative · entry 1 Ling Geoffrey M.D. · CIK 0001800097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,026 F1 · shares: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. F2 · balance_after: Includes 19,231 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| January 12, 2026 Filed Jan 15, 2026 21:15 UTC Amendment | Celularity Inc CELU · Entity 7145 | GrantClass A Common Stock | 19,231 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-002424 · ownership.xml · nonDerivative · entry 1 Ling Geoffrey M.D. · CIK 0001800097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,026 F1 · shares: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest immediately upon grant. F2 · balance_after: Includes 19,231 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest immediately upon grant. Read SEC document |
| December 29, 2025 Filed Dec 30, 2025 21:30 UTC | Celularity Inc CELU · Entity 7145 | GrantStock Options · Derivative | 156,250 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001493152-25-029617 · ownership.xml · derivative · entry 2 Ling Geoffrey M.D. · CIK 0001800097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,490,996 Underlying: Class A Common Stock · 156,250 shares Expires 2035-12-29 F3 · derivative.exercise_date: This option was granted under the 2021 Plan and shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| December 29, 2025 Filed Dec 30, 2025 21:30 UTC | Celularity Inc CELU · Entity 7145 | GrantClass A Common Stock | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-029617 · ownership.xml · nonDerivative · entry 1 Ling Geoffrey M.D. · CIK 0001800097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236,795 F1 · shares: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. F2 · balance_after: Includes 125,000 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 21:30 UTC | Celularity Inc CELU · Entity 7145 | GrantClass A Common Stock | 67,416 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-028780 · ownership.xml · nonDerivative · entry 1 Ling Geoffrey M.D. · CIK 0001800097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,795 F1 · shares: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs vested on December 19, 2025. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 21:15 UTC | Celularity Inc CELU · Entity 7145 | GrantClass A Common Stock | 44,379 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-024631 · ownership.xml · nonDerivative · entry 1 Ling Geoffrey M.D. · CIK 0001800097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,795 F1 · shares: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the date of grant. Read SEC document |
| December 19, 2024 Filed Jan 7, 2025 02:51 UTC | Celularity Inc CELU · Entity 7145 | GrantStock Option (Right to Buy) · Derivative | 84,746 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0001493152-25-001099 · ownership.xml · derivative · entry 2 Ling Geoffrey M.D. · CIK 0001800097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,334,746 Underlying: Class A Common Stock · 84,746 shares Expires 2034-12-19 F3 · derivative.exercise_date: This option was granted under the 2021 Plan and shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, December 19, 2024, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| December 19, 2024 Filed Jan 7, 2025 02:51 UTC | Celularity Inc CELU · Entity 7145 | GrantClass A Common Stock | 67,416 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-001099 · ownership.xml · nonDerivative · entry 1 Ling Geoffrey M.D. · CIK 0001800097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,416 F1 · shares: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, December 19, 2024, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. F2 · balance_after: Includes 67,416 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, December 19, 2024, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| August 31, 2023 Filed Oct 17, 2023 00:06 UTC | Celularity Inc CELU · Entity 7145 | GrantStock Option Grant (Right to Buy) · Derivative | 1,250,000 | $0.00 Strike: $0.32 | $0.00 |
DisclosureSEC source: 0000950170-23-053619 · ownership.xml · derivative · entry 1 Ling Geoffrey M.D. · CIK 0001800097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,250,000 Underlying: Class A Common Stock · 1,250,000 shares Expires 2033-08-31 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's 2021 Equity Incentive Plan. The shares underlying such option will vest in three successive equal annual installments measured from the grant date, subject to the Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| January 07, 2022 Filed Jan 7, 2022 22:31 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 12,855 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002485 · doc4.xml · nonDerivative · entry 1 Ling Geoffrey M.D. · CIK 0001800097 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,790 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:33 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 2,858 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-059433 · doc4.xml · nonDerivative · entry 1 Ling Geoffrey M.D. · CIK 0001800097 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,935 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 13:54 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 2,713 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-044691 · doc4.xml · nonDerivative · entry 1 Ling Geoffrey M.D. · CIK 0001800097 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,077 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| June 09, 2021 Filed Jul 2, 2021 13:54 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001209191-21-044691 · doc4.xml · derivative · entry 2 Ling Geoffrey M.D. · CIK 0001800097 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2031-06-09 F2 · derivative.exercise_date: 100% of the shares subject to the option will vest and become exercisable on June 9, 2022, the one-year anniversary of the grant date. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 17:39 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 2,331 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-025035 · doc4.xml · nonDerivative · entry 1 Ling Geoffrey M.D. · CIK 0001800097 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,364 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| January 05, 2021 Filed Jan 6, 2021 21:58 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 1,782 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002163 · doc4.xml · nonDerivative · entry 1 Ling Geoffrey M.D. · CIK 0001800097 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,033 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 20:22 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 2,616 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-053130 · doc4.xml · nonDerivative · entry 1 Ling Geoffrey M.D. · CIK 0001800097 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,251 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:45 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 1,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-040397 · doc4.xml · nonDerivative · entry 1 Ling Geoffrey M.D. · CIK 0001800097 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,635 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 20:47 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.18 | $0.00 |
DisclosureSEC source: 0001209191-20-036315 · doc4.xml · derivative · entry 1 Ling Geoffrey M.D. · CIK 0001800097 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2030-06-11 F1 · derivative.exercise_date: The option shall vest monthly over a period of 12 months commencing June 11, 2020. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:41 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 1,932 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-023191 · doc4.xml · nonDerivative · entry 1 Ling Geoffrey M.D. · CIK 0001800097 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,932 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 21:06 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | PurchaseCommon Stock | 3,000 | $6.23 | $18,691.50 |
DisclosureSEC source: 0001209191-20-013392 · doc4.xml · nonDerivative · entry 1 Ling Geoffrey M.D. · CIK 0001800097 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 21:06 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.29 | $0.00 |
DisclosureSEC source: 0001209191-20-003937 · doc4.xml · derivative · entry 1 Ling Geoffrey M.D. · CIK 0001800097 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-01-15 F1 · derivative.exercise_date: The option shall vest monthly over a period of 36 months commencing January 15, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.